Suchergebnisse
Aquestive Therapeutics Q2 Earnings Call Highlights
Key Points
- Interested in Aquestive Therapeutics, Inc.? Here are five stocks we like better.
- Aquestive plans to resubmit Anaphylm’s FDA application before the end of Q3 after revised packaging
Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates
Aquestive Therapeutics (AQST) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.14 per share a year ago. These
